• The company mAbxience, specialized in the production of medicines for oncological and autoimmune diseases, expands the access of patients to biological treatments
• With this new plant, the company belonging to Insud Pharma already has three plants, two in Argentina and one in Spain (León).

The mAbxience laboratory, part of the Insud Pharma group, inaugurated a new biosimilar monoclonal antibody production plant in Garín, Buenos Aires province (Argentina). These drugs are used for the treatment of oncological and autoimmune diseases such as rheumatoid arthritis.

With this new plant, the company already has three biosimilar plants, two in Argentina and one in Spain (León).

The project of the new Argentine plant required an investment of 40 million dollars and marks a new milestone in the biopharmaceuticals industry in Latin America. With its start-up, the company manages to double its production capacity with the possibility of meeting the demand of the Argentine and international markets for the next 10 years. From Argentina mAbxience exports biosimilars to Central America, South America, Africa, Asia and the Middle East.

The introduction of biosimilars to the market reduces healthcare spending by 40%, which contributes to the sustainability of healthcare systems and makes it possible to increase the accessibility of more patients to the treatment of these diseases.

"Since mAbxience began to market biosimilar monoclonal antibodies, it managed to save Argentina 400 million dollars in foreign currency and by its mere presence it has forced the prices of the only marketer of imported products that existed in the country to drop," said Hugo Sigman, founder of Group Insud.

The plant currently has 162 employees, and with its start-up, 50 new qualified jobs were created, with the expectation of creating an additional 50 in the coming years. The mAbxience team is made up of biotechnologists, biochemists, biologists, pharmacists and technicians who carry out all operations under the most demanding international standards of Good Manufacturing Practices (GMP).

Since the company's inception, more than 35 patients have been treated with these drugs in Latin America, with a safety profile in line with the original reference product, all of them monitored by a comprehensive pharmacovigilance program. The production of the new plant will allow reaching more patients in Argentina and the world. In Argentina, the commercialization of Rituximab and Bevacizumab is in charge of the ELEA laboratory.

About mAbxience

mAbxience is a global biotechnology company with a decade of experience in the research, development, manufacturing and commercialization of biosimilar monoclonal antibodies. The company seeks to expand patient access to quality treatments for diseases that require high-cost drugs, contributing to the sustainability of healthcare systems.

mAbxience is part of Insud Pharma, a business group founded by Dr. Hugo Sigman and Dr. Silvia Gold. The group has more than 40 years of experience in pharmaceutical activity and has more than 6.000 professionals globally.